Advertisement
Advertisement
ATOS
Atossa Therapeutics, Inc. Common Stock
2.48
USDSponsored
-0.03
-1.20%
Sep 14, 15:59 UTC -4
Closed
After-Market
2.48
0.00
-0.20%
ATOS Earnings Reports
Positive Surprise Ratio
ATOS beat 22 of 34 last estimates.
65%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.96
Implied change from Q2 26 (Revenue/ EPS)
--
/+1.05%
Implied change from Q3 25 (Revenue/ EPS)
--
/-8.57%
Atossa Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 07, 2026, ATOS reported earnings of -0.95 USD per share (EPS) for Q2 26, beating the estimate of -1.04 USD, resulting in a 9.13% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.48% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.96 USD, with revenue projected to reach -- USD, implying an increase of 1.05% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
FAQ
What were Atossa Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Atossa Therapeutics, Inc. Common Stock reported EPS of -$0.95, beating estimates by 9.13%, and revenue of $0.00, 0% as expectations.
How did the market react to Atossa Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -2.48%, changed from $2.42 before the earnings release to $2.36 the day after.
When is Atossa Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Atossa Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Atossa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.96 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.